Abstract Library

#2874 Role of FOXM1 in Aggressive Pancreatic / Pulmonary Neuroendocrine Carcinomas and Anti-Tumor Effect of the FOXM1 Inhibitor Thiostrepton

Introduction: DNA-targeting agents are the main treatment of aggressive pulmonary and pancreatic neuroendocrine carcinomas (NEC). FOXM1 is a transcription factor controlling cell proliferation and DNA repair pathways, playing therefore an important role in tumor progression and chemoresistance.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: De Rycke O, Raffenne J, Lacombe C, Hentic O, Gounant V,

Keywords: neuroendocrine carcinoma, FOXM1, DNA repair, anti-tumor drug,

#1404 The Proteasome Inhibitor Bortezomib Is a Highly Effective Treatment Option for Gastroenteropancreatic Neuroendocrine Neoplasms and Sensitizes to DNA Damaging Therapy In Vitro

Introduction: Gastroenteropancreatic neuroendocrine neoplasms are fairly rare tumors with very heterogeneous behavior and molecular characteristics. Their generally slow proliferation render them virtually resistant to many DNA damaging therapeutic approaches. Bortezomib has been shown to be effective in GEP-NENs in vitro but has been withdrawn from clinical assessment due to a small phase II study on bortezomib monotherapy in 2004.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Briest F

Authors: Briest F, Christen F, Worpenberg L, Welzel M, Freitag H,

Keywords: GEP-NEN, targeted therapy, DNA repair, chemotherapy,

#733 Analysis of Predictive Markers of Response to Chemotherapy in Microdissected Components of Mixed Neuroendocrine/non-Neuroendocrine Carcinomas

Introduction: Mixed neuroendocrine (NE)/non-NE carcinomas lack pathological or molecular prognostic or predictive markers.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Volante M

Authors: Volante M, Monica V, Birocco N, Daniele L, Busso S,

Keywords: mixed carcinomas, molecular analysis, prognosis ,

#401 Status of DNA Repair and Cell Proliferation Markers in High Grade Neuroendocrine Carcinoma of the Uterine Cervix (cNEC) Compared to Small Cell Carcinoma of the Lung (SCLC)

Introduction: Most patients (pts) with cNEC are treated with chemotherapy regimens used for SCLC due to both tumors’ histological similarity and aggressive behavior.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Naraev B, Racila E, Goodheart M, Syrbu S, O'Dorisio T,

Keywords: neuroendocrine, carcinoma, cervix, DNA, repair, proliferation, lung,

#55 Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors

Introduction: Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Koumarianou A, Zilos A, Syrios J, Kanakis G, Antoniou S,

Keywords: GEPNETs, temozolamide, bevacizumab, somatostatin analogue,